List Criteria By Farma ter Verantwoording - 17th December 2020 Share FacebookTwitterWhatsAppLinkedinEmail A2. Commits to comply with human rights standards in product development & marketing T1. Publishes its R&D costs. T2. Publishes its profit margin. T3. The company publishes the average and/or marginal costs of production. T4. Publishes its production capacity. T5. The company publishes the public subsidies it received during product development and/or testing T6. Publishes the text of licensing agreements. T7. Registers its clinical trials in public repositories. C1. The company commits to C-TAP or MPP C2. Commits to not enforcing the exclusive rights of Covid-19 related patents. C3. Supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator. E1. The company makes the active ingredient available on reasonable grounds. [ therapeutics only] E2. Commits to full technology transfer to other manufacturers. E3. Commits to non-profit or ‘fair’ pricing. E6. Agrees to waive exclusive rights in regulatory test data [where applicable]. E4. Equitably distributes supplies globally. [vaccines only] E5. The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable] A1. Publishes a global access plan for its product.